Management of kidney cancer in Asia: Resource-stratified guidelines from the Asian Oncology Summit 2012

The Lancet Oncology

Volumn 13, Issue 11, 2012, Pages

  Chiong, Edmund ^a   Tay, Miah Hiang ^b   Tan, Min Han ^c   Kumar, Santosh ^d   Sim, Hong Gee ^e   Teh, Bin Tean ^f   Umbas, Rainy ^g   Chau, Noan Minh ^f  

^a NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^b GLENEAGLES HOSPITAL   (Singapore)

^c INSTITUTE OF BIOENGINEERING AND NANOTECHNOLOGY   (Singapore)

^d CHRISTIAN MEDICAL COLLEGE   (India)

^e SINGAPORE GENERAL HOSPITAL   (Singapore)

^f DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^g UNIVERSITY OF INDONESIA   (Indonesia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AXITINIB; BEVACIZUMAB; EVEROLIMUS; INTERLEUKIN 2; MEDROXYPROGESTERONE; PAZOPANIB; PLACEBO; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ASIA; CANCER SURGERY; CLASSIFICATION; CLINICAL OBSERVATION; CONSENSUS; CRYOTHERAPY; CYTOREDUCTIVE SURGERY; DRUG COST; DRUG DOSE INCREASE; DRUG MEGADOSE; EVIDENCE BASED PRACTICE; FINANCIAL MANAGEMENT; HEALTH CARE PERSONNEL; HEALTH CARE PLANNING; HUMAN; KIDNEY CANCER; KIDNEY METASTASIS; NEPHRECTOMY; ONCOLOGIST; PARTIAL NEPHRECTOMY; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RECOMMENDED DRUG DOSE; REVIEW; SINGAPORE; SKILL; SYSTEMIC THERAPY; UROLOGIST; WORKSHOP;

ASIA; CARCINOMA, RENAL CELL; DEVELOPING COUNTRIES; DISEASE MANAGEMENT; GUIDELINES AS TOPIC; HUMANS; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84868089265     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70433-3     Document Type: Review

References (92)

1. Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev 2008, 34:193-205.
2. Naito S, Tomita Y, Rha SY, et al. Kidney Cancer Working Group report. Jpn J Clin Oncol 2010, 40(suppl 1):51-56.
3. GLOBOCAN 2008: Most frequent cancers IARC, (accessed June 25, 2012). http://globocan.iarc.fr/factsheets/populations/factsheet.asp?uno=900.
4. Chow WH, Devesa SS, Warren JL, Fraumeni JF Rising incidence of renal cell cancer in the United States. JAMA 1999, 281:1628-1631.
5. Hock LM, Lynch J, Balaji KC Increasing incidence of all stages of kidney cancer in the last 2 decades in the United States: an analysis of surveillance, epidemiology and end results program data. J Urol 2002, 167:57-60.
6. Mathew A, Devesa SS, Fraumeni JF, Chow WH Global increases in kidney cancer incidence, 1973-1992. Eur J Cancer Prev 2002, 11:171-178.
7. Tan MH, Li H, Choong CV, et al. The Karakiewicz nomogram is the most useful clinical predictor for survival outcomes in patients with localized renal cell carcinoma. Cancer 2011, 117:5314-5324.
8. Tan MH, Kanesvaran R, Li H, et al. Comparison of the UCLA Integrated Staging System and the Leibovich score in survival prediction for patients with nonmetastatic clear cell renal cell carcinoma. Urology 2010, 75:1365-1370.
9. Fujii Y, Saito K, Iimura Y, et al. External validation of the Mayo Clinic cancer specific survival score in a Japanese series of clear cell renal cell carcinoma. J Urol 2008, 180:1290-1296.
10. Chiong E, Consigliere D, Esuvaranathan K Renal tumours: a common incidental finding. Singapore Med J 2007, 48:495-502.
11. Pantuck AJ, Zisman A, Belldegrun AS The changing natural history of renal cell carcinoma. J Urol 2001, 166:1611-1623.
12. Miller DC, Ruterbusch J, Colt JS, et al. Contemporary clinical epidemiology of renal cell carcinoma: insight from a population based case-control study. J Urol 2010, 184:2254-2258.
13. Skinner DG, Colvin RB, Vermillion CD, Pfister RC, Leadbetter WF Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases. Cancer 1971, 28:1165-1177.
14. Jayson M, Sanders H Increased incidence of serendipitously discovered renal cell carcinoma. Urology 1998, 51:203-205.
15. Lam JS, Shvarts O, Leppert JT, Figlin RA, Belldegrun AS Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol 2005, 173:1853-1862.
16. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999, 17:2530-2540.
17. Anderson BO, Yip CH, Smith RA, et al. Guideline implementation for breast healthcare in low-income and middle-income countries: overview of the Breast Health Global Initiative Global Summit 2007. Cancer 2008, 113(suppl 8):2221-2243.
18. NCCN Clinical Guidelines in Oncology: Kidney Cancer Version 2.2012 (accessed April 9, 2012). http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site.
19. Blom JH, van Poppel H, Marechal JM, et al. Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. Eur Urol 2009, 55:28-34.
20. Pantuck AJ, Zisman A, Dorey F, et al. Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. J Urol 2003, 169:2076-2083.
21. Canfield SE, Kamat AM, Sanchez-Ortiz RF, Detry M, Swanson DA, Wood CG Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease (clinical stage TxN1-2M0): the impact of aggressive surgical resection on patient outcome. J Urol 2006, 175:864-869.
22. Van Poppel H, Becker F, Cadeddu JA, et al. Treatment of localised renal cell carcinoma. Eur Urol 2011, 60:662-672.
23. Ono Y, Kinukawa T, Hattori R, et al. Laparoscopic radical nephrectomy for renal cell carcinoma: a five-year experience. Urology 1999, 53:280-286.
24. Lee SE, Ku JH, Kwak C, Kim HH, Paick SH Hand assisted laparoscopic radical nephrectomy: comparison with open radical nephrectomy. J Urol 2003, 170:756-759.
25. Hemal AK, Kumar A, Kumar R, Wadhwa P, Seth A, Gupta NP Laparoscopic versus open radical nephrectomy for large renal tumors: a long-term prospective comparison. J Urol 2007, 177:862-866.
26. Portis AJ, Yan Y, Landman J, et al. Long-term followup after laparoscopic radical nephrectomy. J Urol 2002, 167:1257-1262.
27. Permpongkosol S, Chan DY, Link RE, et al. Long-term survival analysis after laparoscopic radical nephrectomy. J Urol 2005, 174:1222-1225.
28. Jeong W, Rha KH, Kim HH, et al. Comparison of laparoscopic radical nephrectomy and open radical nephrectomy for pathologic stage T1 and T2 renal cell carcinoma with clear cell histologic features: a multi-institutional study. Urology 2011, 77:819-824.
29. Lerner SE, Hawkins CA, Blute ML, et al. Disease outcome in patients with low stage renal cell carcinoma treated with nephron sparing or radical surgery. J Urol 1996, 155:1868-1873.
30. Patard JJ, Shvarts O, Lam JS, et al. Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. J Urol 2004, 171:2181-2185.
31. Lee CT, Katz J, Shi W, Thaler HT, Reuter VE, Russo P Surgical management of renal tumors 4 cm or less in a contemporary cohort. J Urol 2000, 163:730-736.
32. Crepel M, Jeldres C, Sun M, et al. A population-based comparison of cancer-control rates between radical and partial nephrectomy for T1A renal cell carcinoma. Urology 2010, 76:883-888.
33. Belldegrun A, Tsui KH, deKernion JB, Smith RB Efficacy of nephron-sparing surgery for renal cell carcinoma: analysis based on the new 1997 tumor-node-metastasis staging system. J Clin Oncol 1999, 17:2868-2875.
34. Leibovich BC, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. J Urol 2004, 171:1066-1070.
35. Dash A, Vickers AJ, Schachter LR, Bach AM, Snyder ME, Russo P Comparison of outcomes in elective partial vs radical nephrectomy for clear cell renal cell carcinoma of 4-7 cm. BJU Int 2006, 97:939-945.
36. Thompson RH, Siddiqui S, Lohse CM, Leibovich BC, Russo P, Blute ML Partial versus radical nephrectomy for 4 to 7 cm renal cortical tumors. J Urol 2009, 182:2601-2606.
37. Van Poppel H, Da Pozzo L, Albrecht W, et al. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol 2011, 59:543-552.
38. McKiernan J, Simmons R, Katz J, Russo P Natural history of chronic renal insufficiency after partial and radical nephrectomy. Urology 2002, 59:816-820.
39. Zorn KC, Gong EM, Orvieto MA, et al. Comparison of laparoscopic radical and partial nephrectomy: effects on long-term serum creatinine. Urology 2007, 69:1035-1040.
40. Huang WC, Elkin EB, Levey AS, Jang TL, Russo P Partial nephrectomy versus radical nephrectomy in patients with small renal tumors-is there a difference in mortality and cardiovascular outcomes?. J Urol 2009, 181:55-61.
41. Russo P The role of surgery in the management of early-stage renal cancer. Hematol Oncol Clin North Am 2011, 25:737-752.
42. Kunkle DA, Egleston BL, Uzzo RG Excise, ablate or observe: the small renal mass dilemma-a meta-analysis and review. J Urol 2008, 179:1227-1233.
43. Weight CJ, Kaouk JH, Hegarty NJ, et al. Correlation of radiographic imaging and histopathology following cryoablation and radio frequency ablation for renal tumors. J Urol 2008, 179:1277-1281.
44. Raman JD, Stern JM, Zeltser I, Kabbani W, Cadeddu JA Absence of viable renal carcinoma in biopsies performed more than 1 year following radio frequency ablation confirms reliability of axial imaging. J Urol 2008, 179:2142-2145.
45. Chawla SN, Crispen PL, Hanlon AL, Greenberg RE, Chen DY, Uzzo RG The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. J Urol 2006, 175:425-431.
46. Abou Youssif T, Kassouf W, Steinberg J, Aprikian AG, Laplante MP, Tanguay S Active surveillance for selected patients with renal masses: updated results with long-term follow-up. Cancer 2007, 110:1010-1014.
47. Abouassaly R, Lane BR, Novick AC Active surveillance of renal masses in elderly patients. J Urol 2008, 180:505-508.
48. Rosales JC, Haramis G, Moreno J, et al. Active surveillance for renal cortical neoplasms. J Urol 2010, 183:1698-1702.
49. Crispen PL, Viterbo R, Boorjian SA, Greenberg RE, Chen DY, Uzzo RG Natural history, growth kinetics, and outcomes of untreated clinically localized renal tumors under active surveillance. Cancer 2009, 115:2844-2852.
50. Kumar A, Gupta NP, Hemal AK A single institution experience of 141 cases of laparoscopic radical nephrectomy with cost-reductive measures. J Endourol 2009, 23:445-449.
51. Bennett RT, Lerner SE, Taub HC, Dutcher JP, Fleischmann J Cytoreductive surgery for stage IV renal cell carcinoma. J Urol 1995, 154:32-34.
52. Chiong E, Wood CG, Margulis V Role of cytoreductive nephrectomy in renal cell carcinoma. Future Oncol 2009, 5:859-869.
53. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001, 358:966-970.
54. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001, 345:1655-1659.
55. Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004, 171:1071-1076.
56. Choueiri TK, Xie W, Kollmannsberger C, et al. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol 2011, 185:60-66.
57. Karam JA, Wood CG The role of surgery in advanced renal cell carcinoma: cytoreductive nephrectomy and metastasectomy. Hematol Oncol Clin North Am 2011, 25:753-764.
58. Biswas S, Kelly J, Eisen T Cytoreductive nephrectomy in metastatic clear-cell renal cell carcinoma: perspectives in the tyrosine kinase inhibitor era. Oncologist 2009, 14:52-59.
59. Krambeck AE, Leibovich BC, Lohse CM, Kwon ED, Zincke H, Blute ML The role of nephron sparing surgery for metastatic (pM1) renal cell carcinoma. J Urol 2006, 176:1990-1995.
60. Hutterer GC, Patard JJ, Colombel M, et al. Cytoreductive nephron-sparing surgery does not appear to undermine disease-specific survival in patients with metastatic renal cell carcinoma. Cancer 2007, 110:2428-2433.
61. Capitanio U, Zini L, Perrotte P, et al. Cytoreductive partial nephrectomy does not undermine cancer control in metastatic renal cell carcinoma: a population-based study. Urology 2008, 72:1090-1095.
62. Finelli A, Kaouk JH, Fergany AF, Abreu SC, Novick AC, Gill IS Laparoscopic cytoreductive nephrectomy for metastatic renal cell carcinoma. BJU Int 2004, 94:291-294.
63. Rabets JC, Kaouk J, Fergany A, Finelli A, Gill IS, Novick AC Laparoscopic versus open cytoreductive nephrectomy for metastatic renal cell carcinoma. Urology 2004, 64:930-934.
64. Matin SF, Madsen LT, Wood CG Laparoscopic cytoreductive nephrectomy: the MD Anderson Cancer Center experience. Urology 2006, 68:528-532.
65. Abel EJ, Wood CG Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy. Nat Rev Urol 2009, 6:375-383.
66. Nanus DM, Garino A, Milowsky MI, Larkin M, Dutcher JP Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer 2004, 101:1545-1551.
67. Pathology and genetics: tumours of the urinary system and male genital organs 2004, 65. IARC, Lyon, France. J.N. Eble, G. Sauter, J.I. Epstein, I.A. Sesterhenn (Eds.).
68. Chowdhury S, Matrana MR, Tsang C, Atkinson B, Choueiri TK, Tannir NM Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions. Hematol Oncol Clin North Am 2011, 25:853-869.
69. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005, 23:133-141.
70. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet 1999, 353:14-17.
71. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005, 1. CD001425.
72. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002, 20:289-296.
73. Wu B, Dong B, Xu Y, et al. Economic evaluation of first-line treatments for metastatic renal cell carcinoma: a cost-effectiveness analysis in a health resource-limited setting. PloS One 2012, 7:e32530.
74. NCCN Asia Consensus Statement: Kidney Cancer Version 2.2011 (accessed Aug 29, 2012). http://www.nccn.org/professionals/physician_gls/PDF/kidney-asia.pdf.
75. Ljungberg B, Cowan NC, Hanbury DC, et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 2010, 58:398-406.
76. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-124.
77. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27:3584-3590.
78. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007, 370:2103-2111.
79. Escudier B, Bellmunt J, Negrier S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010, 28:2144-2150.
80. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008, 26:5422-5428.
81. Rini BI, Halabi S, Rosenberg JE, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010, 28:2137-2143.
82. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010, 28:1061-1068.
83. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356:2271-2281.
84. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134.
85. Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009, 27:3312-3338.
86. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011, 378:1931-1939.
87. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372:449-456.
88. Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010, 116:4256-4265.
89. Gore ME, Szczylik C, Porta C, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 2009, 10:757-763.
90. Wada Y, Takahashi W, Kawano Y, Eto M Current status of pharmacotherapy against metastatic renal cell carcinoma in Japan. Int J Urol 2012, 19:284-295.
91. Uemura H, Shinohara N, Yuasa T, et al. A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety. Jpn J Clin Oncol 2010, 40:194-202.
92. Escudier B, Szczylik C, Hutson TE, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27:1280-1289.